Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Conditions: Endometrial Cancer Interventions: Drug: Lurbinectedin; Drug: Dostarlimab Sponsors: Vall d ' Hebron Institute of Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials